• The Evolving Role Of Pharmacovigilance

    New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events. Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug development process. By Dan Schell, Life Science Leader magazine

  • The Pharma Veteran

    Blockbusters, megamergers, government investigations — Fred Hassan has experienced them all during his nearly 40-year career.

  • A New Breed Of Generics Company

    I admit it — I was skeptical of the claims Alvogen was making. Prior to typing a single word on this two-year-old generics company, I encountered claims such as “creating the pharmaceutical company of tomorrow … ,” “a radical new business model … ,” and “Alvogen will be one of the world’s 10 biggest generic drugmakers by revenues in five years.”

  • A Closer Look At The Business Benefits Of Clean-In-Place (CIP) Systems

    Malcolm McLaughlin, VP, product & business development, Alconox; and Chris Yessayan, CEO, MORK Process, answer questions about clean-in-place processes in pharma manufacturing. 

  • Building A Generics Giant

    She’s been with the company for 19 years, and when she started, there were about 500 employees and approximately $100 million in sales.

  • Can Your Cold Chain Hurt Your Company's Brand?

    Consider how important it is for the physicians administering your drugs to have a good perception about your company. And by good perception, I don’t mean that they just are satisfied with the drugs you produce, I mean they like the drugs and your company in general; they feel confident that you’re top-notch. Sure, there is a lot of marketing that goes into creating that perception, but what you may not realize is that your cold chain processes and technologies can have just as big an impact on a customer’s perception as any advertising or marketing campaign. 

  • Double-Digit Growth: The Next Step For Dr. Reddy's

    It’s 6:30 p.m. in Hyderabad, India, and G.V. Prasad is not where I expected him to be. The vice chairman and CEO of the $1.2B Dr. Reddy’s Laboratories, the second-largest pharmaceutical company in India, is not in his office surrounded by lawyers and PR staffers poised to interject during our interview with their spin on a particular topic. 

  • A Q&A With Brik Eyre, GM Of Baxter Healthcare BioPharma Solutions

    Brik Eyre: The CMO industry has become increasingly competitive. There continues to be overcapacity in the market. We are seeing an increase in globalization, customer service philosophies such as on-time delivery commitments, expansion of service offerings (i.e. additional regulatory, development, and packaging services), and product innovation as a way for the industry to remain competitive.

  • Tips For Enterprisewide ERP Deployment In Pharma

    This month Life Science Leader investigates the topic of ERP (enterprise resource planning). To do so, we gathered input from two companies that have recently implemented ERP systems — Cayman Chemical, which manufactures biochemicals, and Synalloy Corp., which produces specialty chemicals for the pharma industry. 

  • The Changing Business Of Drug Development

    It has been said that one of the key changes pharma companies will need to make is to adopt more rapid drug development processes with the intention to eliminate unsuccessful compounds sooner and promote successful ones more quickly. Do you agree with this assumption?

  • Technology Roundtable: EDC (Electronic Data Capture)

    How Do You Define EDC? Does It Start With An eCRF, Or Can It Start With A Physical CRF? By Dan Schell, Life Science Leader magazine

  • The Transformation Of Sanofi-Aventis U.S.

    The exclusive Life Science Leader interview with Gregory Irace, president and CEO of sanofi-aventis U.S. By Dan Schell, Life Science Leader magazine

  • A View From The Top: Q&A With AstraZeneca CEO David Brennan

    In 2008, AstraZeneca helped more than 440,000 people save more than $612M on their medicines through our prescription savings programs.


Dan Schell

Dan Schell is Chief Editor of Clinical Leader where he writes about topics related to clinical trial operations. Previously, he served as the Editorial Director of Life Science Leader magazine, another Life Science Connect community, for 14 years. In this role, he worked with the publication’s internal and external writers and editors on choosing the best topics for articles as well as refining all content to meet Life Science Leader’s high editorial standards. Prior to his work with Life Science Leader, he worked as an editor and copy editor for the publication’s parent company, VertMarkets (now called Life Science Connect). He joined the company in 2000 after 10 years of working for Encompass Health (previously Healthsouth) in marketing and business development and four years at an advertising agency.